Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroko Bando

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|February 27, 2019
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trialNoriko Sagawa, Shinji Ohno, Takahiro Hiratsuka, et al.
Japanese Journal of Clinical Oncology|September 28, 2010
The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancerMasakazu Toi, Yasuo Ohashi, Adeline Seow, et al.
JACC. Asia|June 19, 2026
Predicting Anthracycline-Induced Cardiotoxicity Using the HFA-ICOS Risk Score: A Validation Study From AIC RegistryAtsuko Suzuki, Keiko Inoue, Tomoko Machino-Ohtsuka, et al.
Annals of Surgical Oncology|August 16, 2015
Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast CancerTomoharu Sugie, Takayuki Kinoshita, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|July 18, 2025
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)Hiroko Bando, Aya Ueda, Kaori Terata, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2021
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort studyKiyo Tanaka, Norikazu Masuda, Naoki Hayashi, et al.
Breast Cancer Research and Treatment|March 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyNorikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, et al.
Investigational New Drugs|August 25, 2020
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|April 3, 2021
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)Manabu Futamura, Mari Oba, Norikazu Masuda, et al.
Breast Cancer Research and Treatment|January 19, 2020
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancerNorikazu Masuda, Shoichiro Ohtani, Toshimi Takano, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|February 27, 2019
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trialNoriko Sagawa, Shinji Ohno, Takahiro Hiratsuka, et al.
Japanese Journal of Clinical Oncology|September 28, 2010
The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancerMasakazu Toi, Yasuo Ohashi, Adeline Seow, et al.
JACC. Asia|June 19, 2026
Predicting Anthracycline-Induced Cardiotoxicity Using the HFA-ICOS Risk Score: A Validation Study From AIC RegistryAtsuko Suzuki, Keiko Inoue, Tomoko Machino-Ohtsuka, et al.
Annals of Surgical Oncology|August 16, 2015
Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast CancerTomoharu Sugie, Takayuki Kinoshita, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|July 18, 2025
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)Hiroko Bando, Aya Ueda, Kaori Terata, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2021
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort studyKiyo Tanaka, Norikazu Masuda, Naoki Hayashi, et al.
Breast Cancer Research and Treatment|March 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyNorikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, et al.
Investigational New Drugs|August 25, 2020
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|April 3, 2021
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)Manabu Futamura, Mari Oba, Norikazu Masuda, et al.
Breast Cancer Research and Treatment|January 19, 2020
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancerNorikazu Masuda, Shoichiro Ohtani, Toshimi Takano, et al.
Pageof 13